Ted Haack joined LatticePoint in July 2016 and provides advisory services to early-stage companies, including pharma, biotech and the cell and gene therapy space. He has advised on market access and pricing strategy, EMA Adaptive Pathways, international expansion, talent acquisition, and key customer relationships and engagement. Prior to consulting, he spent 17 years working in the pharmaceutical industry and headed the Market Access function for Genzyme’s Rare Disease Business Unit and Pfizer’s Head of Head of Market Access, Primary Care BU. Before joining Pfizer, he spent 7 years at Schering-Plough in various regional and affiliate finance roles.
Ted began his career at Deloitte & Touche, including two years in Frankfurt, Germany and is a qualified SEC Audit Committee Financial Expert and CPA (inactive). He was appointed as an Independent Director of Promethera Biosciences (BE) in April 2019. He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.